$15M Boost for CardioInsight, Heart-Mapping Firm

November 13, 2013
60 Views

CardioInsightFirst published on MedCityNews.comCardioInsight Technologies said today that it had secured “long-term strategic financing” that will allow it to complete ongoing clinical trial

CardioInsightFirst published on MedCityNews.comCardioInsight Technologies said today that it had secured “long-term strategic financing” that will allow it to complete ongoing clinical trials in Europe, advance product development programs and pursue regulatory clearance for its cardiac mapping technology in the U.S.

The financing will provide an initial investment of $15 million, the medical device company said.

Formed in 2006 with technology from Cleveland’s Case Western Reserve University, CardioInsight uses an electrode vest that’s worn by a patient to collect electrical data from the surface of the body. It then combines that data with anatomical images of the heart from a CT scan, to generate real-time, 3D, beat-by-beat maps of electrical activity in the heart.

Doctors may use cardiac mapping to help diagnose and treat electrical abnormalities of the heart, like arrhythmia and heart failure. Currently it’s done in an EP lab, where technicians insert catheters into various locations around the patient’s heart to identify the arrhythmia and correct it via ablation. CardioInsight positions its device as a non-invasive way to perform cardiographic mapping for diagnosis of arrhythmias.

The device, called ECVUE, got CE Mark clearance in 2011 and has been used on more than 800 patients in Europe, according to the company. It’s not yet been cleared by the FDA, and a company representative had not returned a call at time of publishing regarding progress with U.S. commercialization.

The new funding follows a $7.5 million Series C raised last year. Based on my calculations using past reports, the new $15 million would bring the total raised by the company to nearly $35 million. Among existing investors are Draper Triangle Ventures, Case Technology Ventures and Jumpstart Ventures (disclosure: Jumpstart is also an investor in MedCity Media).

Boston Scientific, St. Jude Medical and Johnson & Johnson subsidiary Biosense Webster are competitors in the cardiac mapping space.

You may be interested

Wellness
35 shares310 views

7 Super Foods that Boost Immunity

Amy Trotter - Jun 22, 2017

If you are looking to shake the pesky colds and flus that make the colder months unbearable, look no further…

Causes and Consequences of Skin Irritation
Home Health
65 shares448 views
Home Health
65 shares448 views

Causes and Consequences of Skin Irritation

Rehan Ijaz - Jun 21, 2017

Skin ailments are the most common health problem that Americans face. Unfortunately, even seemingly benign skin problems such as acne…

A Changing World: 4 Things that will Change Healthcare in the next 10 Years
Health care
50 shares624 views
Health care
50 shares624 views

A Changing World: 4 Things that will Change Healthcare in the next 10 Years

Kara Masterson - Jun 20, 2017

Obamacare and the possibility of significant repeal-and-replace plans have made the future of healthcare highly controversial subjects for many Americans.…